Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2017-10-20 Proxy Solicitation & In…
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Proxy Statement filed on Schedule 14A with the SEC, related to the 2017 Annual Meeting of Stockholders of Galectin Therapeutics Inc. It includes detailed information about the meeting agenda, voting procedures, board nominees, and other shareholder matters. Proxy Statements are materials sent to shareholders to provide information and solicit votes for meetings. The document is not an Annual Report, Earnings Release, or other financial report, but rather a solicitation document for shareholder voting. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length and content confirm it is the full proxy statement, not just an announcement or summary.
2017-10-20 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is under Item 5.02, which discusses the departure of a director from the board and related governance matters. There is no financial data or detailed financial reporting, so it is not an Annual Report (10-K) or Interim Report (IR). The focus is on management changes, specifically the decision of a director not to stand for re-election and related governance issues. This fits the category of Board/Management Information (MANG). The document length is 4624 characters, which is sufficient to contain substantive information about management changes rather than just an announcement of a report. Therefore, the correct classification is MANG with high confidence.
2017-09-22 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-09-08 English
Director's Dealing 2017
Director's Dealing
2017-09-08 English
Director's Dealing 2017
Director's Dealing
2017-09-08 English
Director's Dealing 2017
Director's Dealing
2017-09-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.